Article
Cell Biology
Inge Compter, Danielle B. P. Eekers, Ann Hoeben, Kasper M. A. Rouschop, Bart Reymen, Linda Ackermans, Jan Beckervordersantforth, Noel J. C. Bauer, Monique M. Anten, Pieter Wesseling, Alida A. Postma, Dirk De Ruysscher, Philippe Lambin
Summary: Treatment with chloroquine in combination with radiotherapy and concurrent temozolomide for newly diagnosed glioblastoma showed favorable toxicity and promising overall survival. The maximum tolerated dose was determined to be 200 mg of chloroquine daily. Further clinical studies are supported by these results.
Article
Oncology
Supriya Mallick, Subhash Gupta, Adila Amariyil, Haresh Kunhiparambath, M. A. Laviraj, Seema Sharma, Hari Krishna Raju Sagiraju, Pramod Kumar Julka, Dayanand Sharma, Goura Kishor Rath
Summary: This study evaluated the survival outcomes of glioblastoma (GBM) patients treated with hypofractionated accelerated radiation therapy (HART). The results showed similar survival outcomes between HART and conventional radiotherapy (CRT). After 5 years, the HART group had a 5-year overall survival rate of 18.4% compared to 3.8% in the CRT group. Therefore, HART has the potential to become the new standard of care in GBM.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
J. Biau, E. Thivat, E. Chautard, D. Stefan, M. Boone, B. Chauffert, C. Bourgne, D. Richard, I Molnar, S. Levesque, R. Bellini, F. Kwiatkowski, L. Karayan-Tapon, P. Verrelle, C. Godfraind, X. Durando
Summary: This phase 1 trial aimed to determine the maximum tolerated dose of a p38-MAPK inhibitor, ralimetinib, in combination with radiotherapy and chemotherapy for newly diagnosed GBM patients. The study found that the MTD of ralimetinib was 100 mg/12 h, with the main dose-limiting toxicities being hepatic cytolysis and rash.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Loig Vaugier, Loic Ah-Thiane, Maud Aumont, Emmanuel Jouglar, Mario Campone, Camille Colliard, Ludovic Doucet, Jean-Sebastien Frenel, Carole Gourmelon, Marie Robert, Stephane-Andre Martin, Tanguy Riem, Vincent Roualdes, Loic Campion, Augustin Mervoyer
Summary: The study reviewed elderly patients with GBM referred for 6-week CRT, finding that CRT treatment was feasible for this population, even in the case of post-operative neurological disabilities. Age and neurological disabilities did not necessarily affect patient outcomes.
SCIENTIFIC REPORTS
(2021)
Article
Pharmacology & Pharmacy
Jigang Chen, Xin Tong, Mingyang Han, Songfeng Zhao, Linjin Ji, Yongkai Qin, Zilong He, Yuesong Pan, Chunhui Wang, Aihua Liu
Summary: The study found that RT plus TMZ treatment for elderly GBM patients in the US is associated with higher costs, but offers greater long-term survival and quality of life benefits. However, in China, this treatment strategy is not cost-effective and requires a decrease in the price of TMZ.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Lei She, Xuan Gong, Lin Su, Chao Liu
Summary: The combination therapy of nimotuzumab with radiation therapy and temozolomide shows potential efficacy in newly diagnosed EGFR-positive GBM patients, particularly those with unmethylated MGMT promoter.
Article
Oncology
Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.
Article
Oncology
K. Ina Ly, Leland G. Richardson, Mofei Liu, Alona Muzikansky, Jonathan Cardona, Kevin Lou, Andrew L. Beers, Ken Chang, James M. Brown, Xiaoyue Ma, David A. Reardon, Isabel C. Arrillaga-Romany, Deborah A. Forst, Justin T. Jordan, Eudocia Q. Lee, Jorg Dietrich, Lakshmi Nayak, Patrick Y. Wen, Ugonma Chukwueke, Anita Giobbie-Hurder, Bryan D. Choi, Tracy T. Batchelor, Jayashree Kalpathy-Cramer, William T. Curry, Elizabeth R. Gerstner
Summary: The efficacy of Bavituximab, a monoclonal antibody with anti-angiogenic and immunomodulatory properties, was evaluated in newly diagnosed patients with glioblastoma (GBM) who also received radiotherapy and temozolomide. The study showed that Bavituximab has activity in the treatment of newly diagnosed GBM and resulted in on-target depletion of intratumoral immunosuppressive MDSCs. Elevated pre-treatment expression of myeloid-related transcripts in GBM may predict response to Bavituximab.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Emilie Le Rhun, Felix Boakye Oppong, Maureen Vanlancker, Roger Stupp, Burt Nabors, Olivier Chinot, Wolfgang Wick, Matthias Preusser, Thierry Gorlia, Michael Weller
Summary: Myelosuppression during temozolomide chemoradiotherapy is associated with the survival of patients with newly diagnosed glioblastoma. Female patients experience more marrow toxicity than males. Lymphopenia is related to the overall survival of patients.
Review
Oncology
Carlen A. Yuen, Marissa Barbaro, Aya Haggiagi
Summary: Management of elderly patients with newly diagnosed glioblastoma (eGBM) presents unique challenges. Although progress has been made in defining the optimal therapeutic approach for these patients, many questions remain unanswered.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Oncology
Maciej Harat, Maciej Blok, Izabela Miechowicz, Izabela Wiatrowska, Karolina Makarewicz, Bogdan Malkowski
Summary: This study evaluated the safety and efficacy of simultaneous integrated boost (SIB) planned using dual FET-PET for postoperative GBM treatment. The results showed that SIB with dual FET-PET improved survival outcomes, but there was a risk of radiation necrosis.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Frank Saran, Liam Welsh, Allan James, Catherine McBain, Rao Gattamaneni, Sarah Jefferies, Fiona Harris, Karine Pemberton, Jennifer Schaible, Shaun Bender, Agnieszka Cseh, Michael Brada
Summary: This study aimed to determine the maximum tolerated dose of afatinib in combination with radiotherapy for patients with GBM. The study identified the maximum tolerated dose as 30 mg when combined with daily TMZ and RT, and 40 mg when combined with RT alone. Further studies on afatinib in GBM patients are recommended, focusing on biomarker-based preselection.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
Jan-Michael Werner, Johannes Weller, Garry Ceccon, Christina Schaub, Caroline Tscherpel, Philipp Lohmann, Elena K. Bauer, Niklas Schaefer, Gabriele Stoffels, Christian Baues, Eren Celik, Simone Marnitz, Christoph Kabbasch, Gerrit H. Gielen, Gereon R. Fink, Karl-Josef Langen, Ulrich Herrlinger, Norbert Galldiks
Summary: The study evaluated the value of FET-PET parameters in diagnosing pseudoprogression related to lomustine-temozolomide chemoradiation, finding that TBRmean had the highest accuracy in identifying pseudoprogression. Furthermore, integrating relative changes of TBRmean improved accuracy, and combining static and dynamic parameters increased specificity to 100%.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Maria Martinez-Garcia, Guillermo Velasco, Estela Pineda, Miguel Gil-Gil, Francesc Alameda, Jaume Capellades, Mari Cruz Martin-Soberon, Israel Lopez-Valero, Elena Tovar Ambel, Palmira Foro, Alvaro Taus, Montserrat Arumi, Aurelio Hernandez-Lain, Juan Manuel Sepulveda-Sanchez
Summary: The addition of crizotinib to standard treatment shows promising efficacy and safety in newly diagnosed patients with glioblastoma, providing a potential therapeutic option for this patient population.
Article
Oncology
A. Alafandi, K. A. van Garderen, S. Klein, S. R. van der Voort, D. Rizopoulos, L. Nabors, R. Stupp, M. Weller, T. Gorlia, J. -c. Tonn, M. Smits
Summary: This study retrospectively evaluated the association between postoperative pre-radiotherapy tumour burden and overall survival in patients with newly diagnosed glioblastoma. The results showed that pre-radiotherapy tumour volume was strongly associated with overall survival, while MGMT promoter methylation, age, and performance status were not.
EUROPEAN JOURNAL OF CANCER
(2023)